| a. | Any entity (as defined in section 101(15) of the Bankruptcy Code) who is a Substantial Shareholder (as defined herein) and wishes to effectuate a transfer of Beneficial Ownership of Common Stock that would affect the size of a Substantial Shareholder’s Beneficial Ownership or would result in another entity becoming or ceasing to be a Substantial Shareholder must file with the Court, and serve upon: (i) Impel Pharmaceuticals Inc., 201 Elliot Avenue West, Suite 260, Seattle, WA 98119; (ii) proposed counsel to the Debtors, (a) Sidley Austin, LLP, One South Dearborn Street, Chicago, IL 60603, Attn: Jackson T. Garvey; (iii) counsel to Oaktree Fund Administration, LLC, Sullivan and Cromwell LLP, 535 Madison Avenue, New York, New York, 10022, Attn: Benjamin Beller; (iv) counsel to any statutory committee appointed in these cases; (v) the Office of the U.S. Trustee for the Northern District of Texas, 1100 Commerce Street, Room 976, Dallas, Texas 75242; and (vi) to the extent not listed herein, those parties requesting notice pursuant to Bankruptcy Rule 2002 (collectively, the “Notice Parties”), a declaration of such status, substantially in the form of Exhibit 1A attached to these Procedures (each, a “Declaration of Status as a Substantial Shareholder”), on or before the later of (A) thirty calendar days after the date of the Notice of NOL Order (as defined herein), or (B) ten calendar days after becoming a Substantial Shareholder; provided that, for the avoidance of doubt, the other procedures set forth herein shall apply to any Substantial Shareholder even if no Declaration of Status as a Substantial Shareholder has been filed. |